Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced that its Phase III clinical trial for jacktinib tablets, a Category 1 product candidate for severe alopecia areata, has successfully met its primary endpoint. The multi-center, randomized, double-blinded, placebo-controlled trial was conducted to evaluate the efficacy and safety of jacktinib in patients with severe alopecia areata, with a total of 425 subjects participating. The trial results indicated that the primary efficacy endpoint, which measures the percentage of subjects achieving a score of ≤20 on the 24-week Severity of Alopecia Tool (SALT) scale, showed a significant improvement in both treatment groups compared to placebo, with statistical significance (p<0.0001). Additionally, the drug demonstrated a favorable safety and tolerability profile.
Jacktinib, a Janus kinase (JAK) inhibitor, exerts a potent inhibitory effect on JAK1, JAK2, JAK3, and TYK2, with the most pronounced effect on JAK2 and TYK2. The drug is currently under investigation in multiple clinical studies for a range of immunoinflammatory and fibrotic diseases. These include myelofibrosis, severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, idiopathic pulmonary fibrosis, and moderate to severe plaque psoriasis.- Flcube.com
